

# Engineering Global Pharmaceutical Manufacturing Systems in the New Environment


**Rick Gunyon**  
Global Process Owner – Systems Engineering  
Engineering Technology Center  
Eli Lilly and Company



**William D. Schindel**  
ICTT System Sciences



# Typical Engineering Disciplines in Pharmaceutical Manufacturing



# *What was the “Old Environment” ???*



**For decades pharmaceutical manufacturing relied on ‘quality by inspection’**

**Regulatory compliance took precedence over fundamental improvements**

- Use of “**Good Manufacturing Practices**” (GMPs)
- “Predicate Rules” (laws) and Guidance, e.g.
  - U.S. FDA
  - E.U. EMEA
  - Irish Medicines Board
  - and others....

**For example, applicable U.S. FDA regulations include:**

- 21CFR 210, 211
- 21CFR Part 11
- 21CFR 820

# *What was the “Old Environment” ???*



## **Traditional Drivers:**


- Few revisions to regulatory GMPs interpreted to suggest “status quo”
- Decades of regulatory inspections and enforcement actions provided ‘learning’
- Continued focus on patient safety relied on quality by inspection
- Essential need to remain “compliant with GMPs”
- Regulatory Expectation: “If it wasn’t documented, it didn’t happen.”

## **Outcomes:**

- Conservative designs
- Status quo approaches
- **Excessive Verification, Validation and Documentation practices, e.g.**

1. **DOCUMENTING EVERYTHING**
2. **Reviewing, verifying and documenting that you documented everything**
3. **Documenting and explaining any documentation errors and/or omissions...**
4. **Then Reviewing and Approving these reviews and approvals...**

# *What was the “Old Environment” ???*



**“Documentation-centric  
Quality by Inspection?”**

*....perhaps there is a  
better way....*



## **Pharmaceutical cGMPs**

**for the**

**21<sup>st</sup> Century**

**- A Risk-Based Approach**

**Final Report - Fall 2004**

**Department of Health and Human Services  
U.S. Food and Drug Administration**

**September 2004**

*“The Desired State”*  
*A Mutual Goal of Industry, Society, and Regulators:*

**“A maximally efficient, agile, flexible pharmaceutical manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.”**

**Janet Woodcock, M.D.**

Deputy Commissioner for Operations  
Office of the Commissioner, FDA

October 5, 2005

“Pharmaceutical Quality Systems”  
“Sound process and product understanding”

# What's Driving Change?



## Typical Pharma Manufacturing vs. World Class Operational Excellence (OPEX)

| Key Performance Indicator     | Typical Pharma Plant (2005) | A Winning Pharma Plant | World Class OPEX |
|-------------------------------|-----------------------------|------------------------|------------------|
| <b>Stock Turns (x / Year)</b> | 3 - 5                       | 14                     | 50               |
| <b>OTIF</b>                   | 60 – 80 %                   | 94 %                   | 96 %             |
| <b>RFT</b>                    | 85 – 95 %                   | 96 %                   | 99 %             |
| <b>Cpk</b>                    | 1 - 2                       | 2.5                    | 3.2              |
| <b>OEE</b>                    | 30 %                        | 74 %                   | 92 %             |
| <b>Cycle Time (WIP Hrs.)</b>  | 720                         | 48                     | 8                |

(Source: The Metamorphosis of Manufacturing © IBM Corporation, 2005)

**OITF** = (Order Filled) On Time In Full

**RFT** = Right First Time

**Cpk** = Process Capability Index

**OEE** = Overall Equipment Effectiveness

# Emerging Trends:

## Product and Process Quality Knowledge

## Science-based and Risk-based Business Execution

## Use of First Principles



### Quality by Design


- Process Design via First Principles

### Process Design

- Limited to the Experimental Design Space

### Experimental Data

- Difficult to Assess



# Emerging Trend: Quality by Design (QbD)



## OUTCOMES from QbD:

Robust process & product understanding  
Manufacturing Systems:

- “In-Control”
- “Capable”
- “Compliant”
- “Continuously Improving”



## IMPLICATIONS:

Systems - of - systems performance  
Robust data & knowledge management  
Across the full lifecycle





**Systems Engineering  
Based on First Principles**

# Business Process Workflows



# SE Integration of Business Process Workflows




# Systems Engineering as a Progressive Discipline



## Summary of Approach

Systems Engineering includes scalable and progressive levels: SE, MBSE, PBSE, IBSE



# Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*



| Hierarchy      | Types | Characteristics                                  |
|----------------|-------|--|
| Site           |       | <b>One Site = 1 – 5 Manufacturing Facilities</b> |
| Facility       |       | <b>Typical Facility = 80 – 140 Subsystems</b>    |
| Area           |       | <b>Some are 'Area Systems'</b>                   |
| Cell           |       | <b>Many are 'Cells'</b>                          |
| Unit Operation |       | <b>Cells contain 'Unit Operations'</b>           |

**Without SE, engineering of systems typically focused on the Facility, and the 80 – 140 subsystems within the Facility, regardless of their hierarchy.**

**SE recognizes the Facility is a type of System, and... the Facility and the 80 - 140 subsystems exist at various levels of hierarchical relationships.**

**SE introduces many important concepts, including Emergent Systemic Behavior, Information Modeling, Abstraction Hierarchy vs. Containment Hierarchy, Interoperability, Specialization, Configuration....**

# Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*



| Hierarchy      | Types                               | Characteristics |
|----------------|-------------------------------------|-----------------|
| Site           | <b>1 – 5 Manufacturing Plants</b>   |                 |
|                | <b>United States of America # 1</b> |                 |
|                | <b>United States of America # 2</b> |                 |
|                | <b>Ireland</b>                      |                 |
|                | <b>France</b>                       |                 |
|                | <b>Italy</b>                        |                 |
| Facility       |                                     |                 |
| Area           |                                     |                 |
| Cell           |                                     |                 |
| Unit Operation |                                     |                 |

API = Active Pharmaceutical Ingredient


Parenteral = administered other than via digestive canal, e.g. Injectable, Transdermal

# Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*



| Hierarchy      | Types                        | Typical Facility Characteristics                       |
|----------------|------------------------------|--|
| Site           |                              |  |
| Facility       | <b>Administration</b>        | <b>Primarily Office Space</b>                          |
|                | <b>Manufacturing</b>         | <b>Product Networks by Type of Product / Process</b>   |
|                | <b>R&amp;D / Pilot Plant</b> | <b>Pipeline R&amp;D / Commercialization / Scale Up</b> |
|                | <b>Distribution</b>          | <b>Warehousing, Geographic Repackaging</b>             |
|                | <b>Utilities</b>             | <b>Central Utility Generation &amp; Distribution</b>   |
|                | <b>Multi-purpose</b>         | <b>(Permutations and Combinations of Above)</b>        |
| Area           |                              |  |
| Cell           |                              |  |
| Unit Operation |                              |  |
| Component      |                              |  |

# Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*



| Hierarchy | Types                   | Typical Area Characteristics                         |
|-----------|-------------------------|--|
| Site      |                         |  |
| Facility  |                         |  |
| Area      | <b>General GMP Area</b> | <b>General manufacturing space – GMPs apply</b>      |
|           | <b>Aseptic Products</b> | <b>Free from contamination / cross contamination</b> |
|           | <b>Dry Products</b>     |  |
|           | <b>cGMP Laboratory</b>  | <b>Analytical Lab Operations</b>                     |
|           | <b>Administration</b>   | <b>General office space</b>                          |
|           | <b>Utility</b>          | <b>Central Utility Generation &amp; Distribution</b> |
| Cell      |                         |  |

# Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*



| Hierarchy      | Types                | Typical Cell Characteristics                                    |
|----------------|----------------------|---|
| Site           |                      |   |
| Facility       |                      |   |
| Area           |                      |   |
| Cell           | <b>Dispensing</b>    | <b>Design &amp; Control - Flow of People, Process, Material</b> |
|                | <b>Coating</b>       | <b>Process Safety Critical Operations</b>                       |
|                | <b>Fill / Finish</b> | <b>Coating, Filling</b>   |
|                | <b>Bio Reactor</b>   | <b>Large Molecule Replication – Living Cells</b>                |
|                | <b>Packaging</b>     | <b>Primary and Secondary Packaging, Blister – Packing</b>       |
|                | <b>Labeling</b>      | <b>Identification as required for Country of Distribution</b>   |
| Unit Operation |                      |   |

# Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*



| Hierarchy      | Types                               | Typical Unit Operation Processes |
|----------------|-------------------------------------|----------------------------------|
| Site           |                                     |                                  |
| Facility       |                                     |                                  |
| Area           |                                     |                                  |
| Cell           |                                     |                                  |
| Unit Operation | <b>Transverse Flow Filtration</b>   | <b>Precise Filtration</b>        |
|                | <b>Lyophilization</b>               | <b>Freeze Drying</b>             |
|                | <b>Decontamination (Autoclave)</b>  | <b>Sterilization</b>             |
|                | <b>Roller Coating (Roll Coater)</b> | <b>Tablet Coating</b>            |
|                | <b>Inoculation Lab</b>              | <b>Media Seeding</b>             |


# Pharmaceutical Manufacturing ... *complex and interdependent Systems of systems*




| Hierarchy | Types                          | Typical Characteristics                |
|-----------|--------------------------------|--|
| Utilities | HVAC / Aseptic / Dry / non-GMP | HEPA / Diff. P / Laminar / Humidity    |
|           | Water Utilities                | WFI, HWFI, HPW, PWEC, Potable          |
|           | Gas Utilities                  | Oxygen, Nitrogen, Breathing Air, Steam |
|           | Data Infrastructure            | Enterprise LAN, Automation, SCADA      |
|           | Electric                       | Dual – Feed, Emergency Generation      |
|           | Piped Liquid Distribution      | Site / Local Distribution & Collection |
|           | Aqueous Waste                  | Sanitary Sewer Load                    |
|           | Solid Waste                    | Landfill Impact                        |
|           | Other                          | Noise                                  |

# Hierarchical View: Logical & Physical Systems

## ANSI / ISA S-95





## Typical Engineering Considerations Include:


### Lifecycle States / Interactions

User Needs, Requirements  
Design Development, Design Controls  
Manufacture, Distribution and Storage  
Customer Storage and Use Conditions  
Device and Drug Product Interactions  
Disposal

### Key Considerations

Ease of use, injection force  
Critical assembly characteristics  
Stability, storage conditions  
Ease of use, stability, storage  
Drug delivery volume  
Environmental impact

# Pharmaceutical Product Manufacturing Process Overview




## Typical API Manufacturing

# Systems of Systems


## Interactions of

- Systems
  - Processes



API = Active Pharmaceutical Ingredient

# Typical API Manufacturing



# Basic SE Workflow

## Implementing New Manufacturing Asset




1. Characterize Project
  2. Identify Functional Areas & Stakeholder Representatives
  3. Identify Stakeholder Needs & Resolve Inconsistencies
  4. Translate Needs into Requirements, Technical Specifications and Attributes
  5. Publish Accepted Technical Specifications as Basis of Acquisition
  6. Publish Accepted Requirements as Basis of Design
  7. Purchase / Build Asset
  8. Verification (Commissioning, etc.)
  9. Validation
  10. Release for use
- 
- Basic SE does not rely on modeling of Features, Interactions, States, Roles...
  - Similar to Quality Function Deployment (QFD)


# SE Information Model



Systematica™




Do more with less



# MBSE

## SE Feature Class Model, Pharma Manufacturing




# MBSE

## SE Feature Class Model, Pharma Manufacturing




Delivery Project Team




Operations Professional

# SE Feature Class Model, Pharma Manufacturing




# MBSE


## SE Interaction Class Model




# MBSE SE Interaction Class Model



# Pharma Facility Domain Model (Simplified)



# Bioreactor Domain Model (Simplified)




# Requirements Statements and Attributes



*“During the specified phase, the Bioreactor System shall maintain temperature of the bioreactor vessel contents between [Min Temperature] and [Max Temperature].”*

| Recipe    | Min Temperature | Max Temperature | Control Strategy | Acceptance Criteria |
|-----------|-----------------|-----------------|------------------|---------------------|
| Product A | 68 Degrees F    | 73 Degrees F    | PID Strategy 3   | Test Case 9         |
| Product B | 84 Degrees F    | 89 Degrees F    | PID Strategy 3A  | Test Case 23        |
| Product C | 69 Degrees F    | 73 Degrees F    | PID Strategy 4   | Test Case 25        |




# Implementing and Sustaining SE via a Collaborative Environment



## Web-based Collaborative Platform

Security & Privacy  
Global Real Time Connectivity  
Collaboration Portals  
Documents  
Applications  
Forms  
Blogs  
Wiki



## 1. New Engineering Workflow

Transitioning a mature and highly-skilled engineering staff to the use of SE:

- Basic SE
- MBSE
- PBSE

## 2. Value Creation Outcomes

SE is well-positioned via SE First Principles, but we need to demonstrate:

- Hard Metrics - Quantified ROI
- Anecdotal Success Stories
- SE Workflow Utilization

***Thank you so much !!***

# References



1. Alexander, C. et al 1977. *A pattern language: Towns, buildings, construction.* New York: Oxford U. Press.
2. ASTM 2009. ASTM Standards catalog web site: <http://www.astm.org/catalog.html>
3. Duda, R., et al. 2001. *Pattern classification*, (2nd ed.), New York: Wiley.
4. Eli Lilly and Company corporate web site: <http://www.lilly.com/>
5. EPA 2009. EPA Regulations catalog web site: <http://www.epa.gov/lawsregs/envtopics/index.html>
6. European Medicines Agency, EMEA web site: <http://www.emea.europa.eu/>
7. FDA 2009. U.S. Code of Federal Regulations 21CFR210 web site: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=210.1>
8. FDA 2004a. "Innovation and continuous improvement in pharmaceutical manufacturing — pharmaceutical cGMPs for the 21st century". Dept of Health and Human Services, U.S. Food and Drug Administration. September 2004. <http://www.fda.gov/cder/gmp/gmp2004/manufSCIWP.pdf>
9. FDA 2004b. "Final report on pharmaceutical cGMPs for the 21st century—a risk-based approach". Dept of Health and Human Services, U.S. Food and Drug Administration. September 2004. [http://www.fda.gov/cder/gmp/gmp2004/GMP\\_finalreport2004.htm](http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport2004.htm)
10. FDA 2004c. "Q8 pharmaceutical development ICH draft: Step 2", November 18, 2004. <http://www.fda.gov/cder/guidance/6672.dft.htm>
11. Gamma, E., et al. 1995. *Design patterns: Elements of reusable object-oriented software.* Reading, MA: Addison-Wesley.
12. Haskins, C. 2005. "Application of patterns and pattern languages to systems engineering". Paper presented at the 15th annual international symposium of the international council on systems engineering, Rochester, NY.
13. Hopp, W., and Spearman, M. 2008. *Factory physics*, third edition. McGraw Hill. ISBN-10: 007123246X
14. IBM Corporation 2005. "The metamorphosis of manufacturing: From art to science". © IBM Global Services, Somers, NY.
15. ICH Quality Guidelines 2009, "ICHQ1" – "ICHQ10", International Conference on Harmonisation web site: <http://www.ich.org/cache/compo/276-254-1.html>

# References



16. ICTT 2006. "Enhancing process engineering integration: An application of model-based systems engineering (MBSE)."
17. INCOSE 2009. INCOSE Model driven system design working group web site: <http://www.incose.org/practice/techactivities/wg/mdsd/> .
18. ISA 2009. ISA Standards publications web site: <http://www.isa.org/InTechTemplate.cfm?Section=Standards1&Template=/ContentManagement/AllContentList.cfm&ICID=%2778%2C89%27&PageName=Standards>
19. ISPE 2009. ISPE Guides and publications web site: [http://www.ispe.org/cs/technical\\_documents\\_section/technical\\_documents\\_overview](http://www.ispe.org/cs/technical_documents_section/technical_documents_overview)
20. Lilly 2009. Eli Lilly & Company web site: <http://www.lilly.com>
21. OSHA 2009. OSHA Standards catalog web site: <http://www.osha29cfr.com/>
22. Radspinner. 2004. "Implementation of PAT: An industry perspective." Sanofi-aventis. RPS/FDA/Meeting, London, December, 2004. <http://www.fda.gov/cder/OPS/Radspinner.pdf>
23. PDA 2001, "Real Compliance and How to Achieve It", Russell E. Madsen, PDA J Pharm Sci Technol. 2001 Mar-Apr;55(2):59-64
24. Scherzer. R. 2005. "Quality by design: A challenge to the pharma industry." CAMP, U.S. Food and Drug Administration Science Board, April 2002. <http://www.fda.gov/cder/OPS/Scherzer-Camp/index.htm>
25. Schindel, W. 2005a. Requirements statements are transfer functions: An insight from model-based systems engineering. Paper presented at the annual international symposium of the International Council on Systems Engineering, July, Rochester, NY.
26. Schindel, W. 2005b. Pattern-based systems engineering: An extension of model-based systems engineering. INCOSE TIES tutorial presented at 2005 INCOSE Symposium.
27. \_\_\_, 2007. "Pattern-based systems engineering (PBSE): Outcomes and experiences." IEEE/INCOSE chapter joint meeting, Indianapolis.
28. Schindel, W. and Smith, V. 2002. Results of applying a families-of-systems approach to systems engineering of product line families. Technical Report 2002-01-3086. SAE International.